Solventum Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bryan C. Hanson
- Full Time Employees
- 20,584
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1750 Yankee Doodle Road Eagan MN United States of America 55121
- IPO Date
- Apr 1, 2024
- CIK
- 0001964738
- Website
- solventum.com
- Similar Companies
- Business
- Solventum Corporation (NYSE: SOLV) develops, manufactures and commercializes healthcare solutions at the intersection of health, material and data science, including advanced wound care such as negative pressure wound therapy and surgical incision management; infection prevention and skin integrity products; dental and orthodontic bonding systems and consumables; revenue cycle management and health information systems software; and purification and filtration solutions for biopharmaceutical manufacturers. The company, spun off from 3M and became independently publicly traded on April 1, 2024, after incorporation in 2023 as a successor to 3M's health care business with over 70 years of history, maintains headquarters in St. Paul, Minnesota, and employs more than 20,000 people across approximately 38 countries with significant operations in the United States (over 50% of sales), EMEA, Asia-Pacific including China, and other international markets; it operates through three primary segments post recent divestiture, MedSurg (largest, encompassing advanced wound care, oral care and medical device components), Dental Solutions, and Health Information Systems, serving hospitals, clinics, dental professionals, biopharma firms and healthcare providers. Recent major changes include the February 2025 announcement and subsequent completion of the $4.1 billion sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. expected by end-2025 for net proceeds of about $3.4 billion primarily to reduce debt as part of its multi-phase transformation plan following independence; alongside scheduling an Investor Day in March 2025 to outline long-range strategy and a definitive agreement to acquire Acera Surgical to bolster surgical technologies and patient outcomes.
Company News
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Moderate Buy” from Brokerages
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
SOLV Energy Q2 Earnings Call Highlights
SOLV Energy, Inc. (MWH) Q2 2026 Earnings Call Transcript
SOLV Energy Reports Second Quarter 2026 Financial Results
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Bank of America Corp DE Acquires 9,083 Shares of Solventum Corporation $SOLV
Solventum Q2 Earnings Call Highlights
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
Solventum Corp (SOLV) (Q2 2026) Earnings Call Highlights: Strong Growth and Strategic Separation of HIS Business
Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript
Solventum (SOLV) Q2 Earnings and Revenues Top Estimates
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Solventum to hive off healthcare software business, raises profit forecast
Solventum Reports Second Quarter 2026 Financial Results